What will the average number of measles cases be during Trump's term?
I assess a **72%** chance that the 2025–2028 average annual measles case count will meet the 'Yes' condition (assumed here as average ≥ 2,200 cases/year). The recent 2025 peak and the very strong 2026 trajectory make an above‑2,200 four‑year average the more likely outcome absent major, sustained vaccination gains.
Analysis
**Stage 1 — Blind analysis (ignore market prices):**
- Assumption clarification: the event is interpreted as a binary test of whether the average annual number of confirmed U.S. measles cases across 2025–2028 will be at least ~2,200 cases/year (the prompt repeatedly highlights 2,200–2,300 as the threshold of interest). I explicitly adopt that threshold for the independent probability below.
- Empirical starting point: 2025 had **2,288** confirmed cases. As of July 2, 2026 the U.S. has **2,170** confirmed cases with half the year remaining — a pace that, if sustained, would produce a 2026 total substantially above 2,200 (potentially double the 2025 total). That alone materially raises the likelihood the 4‑year average ≥2,200.
- Mechanics and required sums: to average ≥2,200 across four years the cumulative total for 2025–2028 must be ≥8,800. With 2,288 already in 2025, the remaining three years need to sum to ≥6,512 (an average of ≥2,171/year). Given the current 2026 pace and the structural drivers (large unvaccinated pockets, clustered outbreaks, sustained domestic transmission), that remaining‑years target is plausibly met.
- Structural epidemiology: measles has very high transmissibility and outbreaks concentrate in undervaccinated communities. The news shows **~93–94% of cases are unvaccinated or unknown**, outbreaks account for ~90% of cases, and children are concentrated in case counts — all signs that transmission is being driven by persistent coverage gaps rather than a transient importation spike. Persistent low coverage will sustain multi‑year elevated incidence.
- Countervailing forces: public health responses (targeted campaigns, school‑entry enforcement, emergency immunization clinics), natural depletion of susceptibles in the most affected micro‑populations, and seasonal/measurement variability could pull later-year totals down. But these factors would need to be large and sustained to offset the current elevated baseline across three future years.
- Quantitative judgment: given the high baseline (2025) and the 2026 trajectory, I estimate a **~72%** probability that the 2025–2028 average will be ≥2,200 cases/year. This reflects a central scenario where 2026 remains ≥~2,200 (likely higher), and 2027–2028 stay at least near the 2k range. I model a non‑trivial chance (≈28%) that aggressive interventions, reporting changes, or rapid catch‑up vaccination reduce the later years enough to push the four‑year average below the threshold.
**Stage 2 — Market calibration (look at market prices):**
- The market currently prices **Yes at 0.30 / No at 0.70**. My independent estimate (72%) is substantially higher than the market-implied probability (30%). Possible reasons for the discrepancy: - *Market interpretation ambiguity:* If traders are uncertain about the exact threshold (e.g., different contracts using different cutoffs) they may discount the contract, widening spreads and producing a low Yes price. Ambiguity often suppresses Yes demand. - *Underweighting of 2026 YTD data:* Some traders may view the July 2 YTD count (2,170) as an early-season cluster or reporting artifact and expect strong reversion to the long-term mean, so they underweight the implication of a mid‑year count that already nearly equals 2025's total. - *Optimism about interventions/policy:* The market may be pricing in stronger vaccination drives, state‑level mandates, or federal campaigns during 2026–2028 that significantly close coverage gaps. If traders overestimate the speed/effect of these interventions, the market will underprice Yes. - *Hedging and portfolio flows:* High volume (148k contracts) suggests active trading; some big traders may be short Yes as a hedge against other exposures, depressing the Yes price below the fundamentals.
- Which is likelier — market or my estimate? Given the objective data (2025 already >2,200; 2026 YTD ~2,170 by July 2; high share of unvaccinated cases; outbreak clustering), I believe the market is **undervaluing the tail risk that elevated transmission persists**. If 2026 ends up near or above current pace, the market will likely reprice upward quickly. Conversely, if strong, rapid vaccination campaigns are implemented and prove effective in late 2026–2027, the market's conservative pricing would be vindicated.
- Conclusion of calibration: trade signal — the market's 30% Yes implies either high confidence in rapid remediation or mispricing due to ambiguity and behavioral factors. My independent 72% suggests **Yes is substantially underpriced** and represents a favorable side to buy if one accepts the threshold assumption and the robustness of current 2026 data.
Arguments
For
- Recent empirical momentum is strong: 2025 = 2,288 and 2026 mid‑year is already 2,170 — that pace strongly biases the 4‑year average upward.
- Transmission is driven by persistent coverage gaps: ~93–94% of cases are unvaccinated/unknown, indicating structural vulnerability rather than isolated importation.
- Outbreak structure favors sustained high totals: ~9 out of 10 cases are outbreak‑linked, and clusters in undervaccinated communities can sustain multi‑year transmission chains.
- Prospective loss of measles elimination designation increases baseline risk by signaling endemic reestablishment and reducing some institutional protections against spread.
Against
- Public health authorities can deploy rapid, targeted vaccination campaigns which historically can suppress outbreaks within months if well‑resourced and focused.
- Local depletion of susceptibles in the most affected micro‑populations could naturally reduce outbreak size in later years, producing lower totals in 2027–2028.
- Reporting and classification changes, or an anomalous 2026 surge driven by a few large clusters, could cause mean reversion rather than permanent elevation.
- Political and policy shifts (at federal or state level) could restore stronger mandates or incentives that significantly increase vaccine uptake over a short period.
Key drivers
- Persistence of low MMR coverage in concentrated communities (current data: ~93–94% of cases unvaccinated/unknown).
- Scale and frequency of outbreaks (2026 has ~30 new outbreaks and ~90% of cases in outbreak contexts).
- Public health policy response intensity (state/federal campaigns, school mandates, emergency vaccination clinics).
- Natural epidemic dynamics: depletion of susceptibles in highly affected communities and seasonality of transmission.
- International importations and travel patterns (source seeds for new outbreaks).
Risk factors
- Rapid, large-scale vaccination catch-up campaigns or new mandates that substantially raise coverage quickly.
- Successful targeted outbreak control and contact tracing that substantially reduces secondary transmission.
- Data or reporting revisions downward (case reclassification, delayed confirmations) that reduce apparent 2026 totals.
- Behavioral change reducing contacts in high‑risk communities (voluntary protective behavior, temporary school exclusions).
- Uncertainty over contract threshold/ambiguity leading to market misinterpretation independent of epidemiology.
Scenarios
Best case
Yes best case: 2026 finishes at very high levels (>>2,200), and 2027–2028 remain elevated (2,000–3,500/year) because vaccination gaps persist and outbreaks recur in underimmunized communities. The four‑year cumulative total comfortably exceeds 8,800, producing an average well above the 2,200 threshold.
Most likely
Most likely: 2026 ends above 2,200 (possibly markedly so), 2027 sees partial reduction due to targeted responses but not full correction (approx. 1,800–2,500), and 2028 stabilizes near 1,800–2,200. The four‑year average ends slightly above the 2,200 threshold (consistent with my 72% probability), driven mainly by the large 2025–2026 contributions.
Worst case
No worst case: immediate, well‑coordinated national and state responses close the coverage gap rapidly — intensive campaigns, school‑entry enforcement, and community outreach reduce transmission sharply in late 2026 and the following years. Combined with natural depletion of susceptibles in affected subpopulations, the remaining years average <2,100 and the four‑year mean falls below 2,200.
More from this day
- economyPolymarketEnded
Elon Musk Net Worth on July 31?
AI97%MKT3%Edge+94Hidden GemI assess a very high probability that Elon Musk’s Bloomberg-reported net worth will be less than $0.70T on July 31, 2026; I estimate this at about 97% based on typical asset composition and realistic upside scenarios over the next month.
- CompaniesKalshi1y
Starbucks total global stores in 2026
AI85%MKT10%Edge+75Hidden GemStarbucks is very likely to report above 41,800 total global stores in 2026 — the company is already >41,000 and the incremental number required (~800+) is small relative to the planned pace of expansion.
- pop culturePolymarketEnded
"Minions & Monsters" Opening Weekend Box Office
AI33%MKT96%Edge-63HypedI assess a 33% chance that Minions & Monsters will open below $68M for the 5-day July 1–5 weekend, with the balance favoring a solid holiday opening above that threshold driven by franchise strength and the July 4 boost.